Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Consensus Target Price of $10.21 According to Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $10.25.

A number of equities analysts recently weighed in on CMPX shares. Lifesci Capital lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 22nd. Piper Sandler upped their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Guggenheim reduced their target price on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research note on Wednesday, September 23rd. LADENBURG THALM/SH SH began coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 price target on the stock. Finally, Citizens Jmp dropped their price target on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 23rd.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently modified their holdings of the business. Parallel Advisors LLC purchased a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $28,000. PNC Financial Services Group Inc. lifted its holdings in Compass Therapeutics by 2,572.6% in the first quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock valued at $58,000 after acquiring an additional 10,625 shares during the period. HB Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the 2nd quarter worth $29,000. State of Wyoming acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $31,000. Finally, Pictet Asset Management Holding SA purchased a new stake in Compass Therapeutics during the first quarter worth about $76,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 3.6%

Compass Therapeutics stock opened at $0.98 on Friday. Compass Therapeutics has a twelve month low of $0.83 and a twelve month high of $6.88. The stock has a 50 day moving average of $1.90 and a two-hundred day moving average of $2.59. The stock has a market capitalization of $177.10 million, a price-to-earnings ratio of -2.46 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Equities analysts predict that Compass Therapeutics will post -0.47 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB.